Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world, multi-omics validation of the clinical relevance of molecular taxonomy for myelodysplastic syndromes (MDS).

HemaSphere·2026
Same author

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex.

American journal of hematology·2026
Same author

Molecular-Based Ecosystem to Improve Personalized Medicine in Chronic Myelomonocytic Leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Exposure to Agent Orange and association with myelodysplastic syndromes.

Blood advances·2026
Same author

A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study.

Blood advances·2026
Same author

A phase 1 trial of ibrutinib and azacitidine for higher risk myelodysplastic syndromes (University of California Hematologic Malignancies Consortium Study 1503).

Leukemia research·2025

Related Experiment Video

Updated: May 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K

Prognostic models in myelodysplastic syndromes.

Rafael Bejar1

  • 11Moores Cancer Center, Division of Hematology and Oncology, University of California, San Diego, La Jolla, CA.

Hematology. American Society of Hematology. Education Program
|December 10, 2013
PubMed
Summary

Prognostic scoring systems for myelodysplastic syndromes (MDS) are evolving. Newer models, including molecular markers, aim to improve risk stratification beyond the International Prognostic Scoring System (IPSS).

More Related Videos

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K

Related Experiment Videos

Last Updated: May 5, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

9.0K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

2.0K
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
12:05

Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation

Published on: November 3, 2018

10.8K

Area of Science:

  • Hematology
  • Oncology
  • Medical Informatics

Background:

  • Accurate prognosis is crucial for managing myelodysplastic syndromes (MDS), guiding patient care and treatment decisions.
  • The International Prognostic Scoring System (IPSS) has been the standard for MDS risk stratification since 1997.
  • Limitations of the IPSS and evolving MDS classifications have led to newer prognostic models.

Purpose of the Study:

  • To review prognostic scoring systems for myelodysplastic syndromes (MDS) developed after the original IPSS.
  • To describe the integration of molecular markers into MDS risk stratification.
  • To highlight advancements in predicting patient outcomes in MDS.

Main Methods:

  • Review of existing literature on prognostic scoring systems for MDS.
  • Analysis of the development and validation of newer models like the revised IPSS (IPSS-R).
  • Discussion of the role and challenges of incorporating somatic mutations and molecular markers.

Main Results:

  • Several prognostic models have been developed to address deficiencies in the original IPSS.
  • The revised IPSS (IPSS-R) offers improved risk stratification compared to its predecessor.
  • Somatic mutations are prevalent in MDS and show potential to enhance existing prognostic models.

Conclusions:

  • Current prognostic systems for MDS, while useful, do not incorporate molecular abnormalities.
  • Somatic mutations present a promising avenue for refining MDS risk stratification.
  • Further research is needed to effectively combine molecular data with clinical predictors for optimal patient management.